- Home
- ALKT vs BCRX Comparison
ALKT vs BCRX Comparison
Compare ALKT & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- BCRX
- Stock Information
- Founded
- ALKT 2007
- BCRX 1986
- Country
- ALKT United States
- BCRX United States
- Employees
- ALKT N/A
- BCRX N/A
- Industry
- ALKT EDP Services
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALKT Technology
- BCRX Health Care
- Exchange
- ALKT Nasdaq
- BCRX Nasdaq
- Market Cap
- ALKT 2.3B
- BCRX 1.9B
- IPO Year
- ALKT 2021
- BCRX 1994
- Fundamental
- Price
- ALKT $22.41
- BCRX $8.30
- Analyst Decision
- ALKT Buy
- BCRX Strong Buy
- Analyst Count
- ALKT 9
- BCRX 10
- Target Price
- ALKT $39.89
- BCRX $16.70
- AVG Volume (30 Days)
- ALKT 1.8M
- BCRX 3.4M
- Earning Date
- ALKT 07-30-2025
- BCRX 08-04-2025
- Dividend Yield
- ALKT N/A
- BCRX N/A
- EPS Growth
- ALKT N/A
- BCRX N/A
- EPS
- ALKT N/A
- BCRX N/A
- Revenue
- ALKT $385,456,000.00
- BCRX $557,506,000.00
- Revenue This Year
- ALKT $36.31
- BCRX $37.96
- Revenue Next Year
- ALKT $25.07
- BCRX $8.82
- P/E Ratio
- ALKT N/A
- BCRX N/A
- Revenue Growth
- ALKT 29.63
- BCRX 45.85
- 52 Week Low
- ALKT $19.94
- BCRX $6.02
- 52 Week High
- ALKT $42.29
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- ALKT 41.11
- BCRX 44.63
- Support Level
- ALKT $22.43
- BCRX $8.27
- Resistance Level
- ALKT $23.47
- BCRX $8.59
- Average True Range (ATR)
- ALKT 1.22
- BCRX 0.29
- MACD
- ALKT 0.23
- BCRX 0.05
- Stochastic Oscillator
- ALKT 46.58
- BCRX 34.96
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.